Achaogen

Achaogen is a clinical-stage biopharmaceutical company dedicated to broad-spectrum antibiotic treatments for multidrug-resistant bacterial infections. The company's most advanced candidate drug, ACHN-490, showed positive safety and dosage results in Phase I clinical trials and demonstrated broad-spectrum efficacy in preclinical studies against systemic infections caused by multidrug-resistant (MDR) Gram-negative bacteria such as E. coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa, as well as MRSA. Additionally, the company is conducting preclinical programs in several other areas of interest to address the global emergence of bacterial resistance.